Phase III success for CTI's pacritinib, but second study crucial
This article was originally published in Scrip
Executive Summary
A statistically significant percentage of myelofibrosis patients treated with CTI BioPharma's pacritinib in the Phase III PERSIST-1 clinical trial had a 35% or greater reduction in spleen size versus best available therapy, including particularly large decreases for individuals who are unlikely to be treated effectively with the competing Incyte and Novartis Janus kinase (JAK) inhibitor Jakafi (ruxolitinib).